The combination of human glandular Kallikrein and free prostrate- specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA

Clinical Chemistry

Volumn 45, Issue 11, 1999, Pages 1960-1966

  Magklara, Angeliki ^a,b   Scorilas, Andreas ^a,b   Catalona, William J ^c   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN; TUMOR MARKER;

ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CORRELATION FUNCTION; DISEASE MARKER; HUMAN; IMMUNOASSAY; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 0032714294     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.11.1960     Document Type: Article

References (27)

1. 1. Diamandis EP. Prostate specific antigen - its usefulness in clinical medicine. Trends Endocrinol Metab 1998;9:310-6.
2. 2. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-5.
3. 3. Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 1993;20:653-63.
4. 4. Benson MC, Olsson CA. Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and manage ment. Cancer 1994;74:1667-73.
5. 5. Carter HB, Spearman JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
6. 6. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-4.
7. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
8. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
9. 9. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
10. 10. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996;8(Suppl):55-61.
11. 11. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995;46:187-94.
12. 12. Vashi AR, Wojno KJ, Henricks W, England BA, Vessella RL, Lange PH, et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997;49:19-27.
13. 13. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
14. 14. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275-368.
15. 15. Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997;238:549-55.
16. 16. Woodrun DL, French CM, Hill TM, Roman SJ, Slatore HL, Shaffer JL, et al. Analytical performance of the Tandem-R free PSA immunoassay measuring free prostate-specific antigen. Clin Chem 1997;43:1203-8.
17. 17. Black MH, Magklara A, Obiezu C, Melegos D, Diamandis EP. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin Chem 1999;45:790-9.
18. 18. Rittenhouse HG, Tindall, D, Klee GG, Young CY-F, Bostwick D, Saedi MM, et al. Characterization and evaluation of hK2: a potential prostate cancer marker, closely related to PSA. In: Murphy GP, Khoury S, eds. Proceedings of the First International Consultation on Prostate Cancer, June 1996, Monaco.
19. 19. Charlesworth MC, Young CY, Klee GG, Saedi MS, Mikolajczyk SD, Finlay JA, Tindall DJ. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology 1997;49:487-93.
20. 20. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997;49:857-62.
21. 21. Saedi MS, Hill TM, Goel AS, Kumar A, Roche P. Assessment of the precursor form of human kallikrein 2 (prohK2) as a marker for prostate cancer. J Urol 1997;157:442.
22. 22. Saedi MS, Hill TM, Kuus-Reichel K, Kumar A, Payne J, Mikolajczyk SD, et at. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin Chem 1998;44:2115-9.
23. 23. Klee GG, Goodmanson MK, Jacobsen SJ, Young CY, Finlay JA, Rittenhouse HG, et al. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin Chem 1999;45:800-6.
24. 24. Stenman UH. New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease. Clin Chem 1999;45:753-4.
25. 25. Finlay JA, Evans CL, Day JR, Payne JK, Mikolajczyk SD, Millar LS, et al. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 1998;51:804-9.
26. 26. Becker C, Fernlund P, Lilja H, Hugosson J, Piironen T, Pettersson K. Percent human glandular kallikrein 2 (hK2) to free PSA in serum in the detection of prostate cancer and discrimination of tumor grade [Abstract]. J Urol 1998;159:178.
27. 27. Kwiatkowski MK, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, Tscholl R. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 1998;52:360-5.